Clinical trial
Intrathecal Rituximab in Treating Patients With Recurrent CNS Lymphoma
NCT00416923 · University of California, San Francisco, Other · Completed
Key facts
| NCT number | NCT00416923 |
|---|---|
| Title | Intrathecal Rituximab in Treating Patients With Recurrent CNS Lymphoma |
| Official title | Phase I Study of Intrathecal Rituximab in Patients With Recurrent CNS Lymphoma |
| Lead sponsor | University of California, San Francisco, Other |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Brain and Central Nervous System Tumors, Lymphoma |
| Intervention type | Biological |
| Interventions | rituximab |
| Enrollment | 10 |
| Start date | Aug 1, 2002 |
| Primary completion | Nov 1, 2005 |
| Completion | Apr 1, 2007 |
| First posted | Dec 28, 2006 |
| Last update posted | Feb 16, 2015 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: